WO2007043933A1 - Probiotics to influence fat metabolism and obesity - Google Patents

Probiotics to influence fat metabolism and obesity Download PDF

Info

Publication number
WO2007043933A1
WO2007043933A1 PCT/SE2006/001117 SE2006001117W WO2007043933A1 WO 2007043933 A1 WO2007043933 A1 WO 2007043933A1 SE 2006001117 W SE2006001117 W SE 2006001117W WO 2007043933 A1 WO2007043933 A1 WO 2007043933A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
obesity
probiotics
mice
probiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2006/001117
Other languages
English (en)
French (fr)
Inventor
Kajsa Ohlson
Margit Mahlapuu
Ulla Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007043933(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK06799717.1T priority Critical patent/DK1945235T3/da
Priority to BRPI0616993-7A priority patent/BRPI0616993A2/pt
Priority to ES06799717T priority patent/ES2396865T3/es
Priority to JP2008534487A priority patent/JP2009511469A/ja
Priority to EP06799717A priority patent/EP1945235B1/en
Priority to CA002624890A priority patent/CA2624890A1/en
Priority to AU2006299956A priority patent/AU2006299956B2/en
Priority to EA200800913A priority patent/EA015461B1/ru
Priority to SI200631495T priority patent/SI1945235T1/sl
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Priority to US12/089,433 priority patent/US20080267933A1/en
Priority to CN2006800368040A priority patent/CN101287478B/zh
Priority to PL06799717T priority patent/PL1945235T3/pl
Publication of WO2007043933A1 publication Critical patent/WO2007043933A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/23—Lactobacillus acidophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Definitions

  • the invention relate to use of probiotic bacteria for the manufacture of a food product, feed product, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal product to be used for controlling weight gain, preventing obesity, increasing satiety, prolonging satiation, reducing food intake, reducing fat deposition, improving energy metabolism, enhancing insulin sensitivity, treating obesity and treating insulin insensitivity.
  • Probiotics are defined by ILSE (International life science institute) as added "microorganisms with a beneficial effect on health”. Probiotics are commonly used in foods, feed products and dietary supplements for their influence on gut health, infection and the immunsystem. Some probiotic strains, but not all studied, have also been shown to influence blood cholesterol level and recently the possibility to lower blood pressure by the use of milk products fermented by proteolytic lactic acid bacteria has been found. Thus the interest in probiotics is wide and the central role of the gut flora for gut health and wellbeing and the immune system is strongly established.
  • ILSE International life science institute
  • glucose metabolism An important factor in the metabolic syndrome is the glucose metabolism including the insulin sensitivity. There is a link between body fat deposition, insulin insensitivity and overweight. There is also a link to satiety and satiation. The interactions and relationships between all those functions are complex and it is difficult to identify the exact sequence of events leading to health or disease.
  • a number of genes and their corresponding proteins that are involved in energy homeostasis have been described. Adipose tissue synthesizes a number of proteins with structural resemblance to cytokines and therefore these proteins are named adipokines. Some of those are also synthesised in the gut or the synthesis is regulated from the gut.
  • the nuclear receptor PPAR-gamma is involved in the synthesis of e.g.
  • adiponectine and the synthesis is associated with calorie intake and leptin signalling.
  • Increased synthesis of adiponectine improves insulin sensitivity by increasing fatty-acid transport, oxidation and dissipation in skeletal muscle and by increasing the sensitivity of the hepatocyte to insulin.
  • Another nutritionally regulated adipocyte-derivied factor influencing insulin sensitivity is resistin. Circulating resistin levels are increased in obesity while treatment of mice with resistin resulted in increased glucose production and impaired insulin action. Thus resistin has a function in glucose homeostasis, and acts as an antagonist to insulin action, giving rise to insulin resistance.
  • Resistin-like proteins are also expressed in the gastrointestinal tract (14). The protein apolipoprotein A-IV is secreted by the small intestine in humans and in rodents. The synthesis is stimulated by fat intake and the protein is probably involved in inhibiting food intake after ingestion of fat.
  • apolipoprotein A-IV probably is involved both in the short-time and long-time regulation of food intake.
  • An object of the invention is use of probiotic bacteria for the manufacture of a food product, feed product, dietary supplement, nutritional product , natural remedy, pharmaceutical active formulation and medicinal products to be used for controlling weight gain, preventing obesity, increasing satiety, prolonging satiation, reducing food intake, reducing fat deposition, improving energy metabolism, enhancing insulin sensitivity, treating obesity and treating insulin insensitivity.
  • probiotic bacteria being selected from the group consistion of lactic acid bacteria specially Lactobacillus casei, Lactobacillus acidophilus, and Bifidobacterium lactis, and more preferably Lactobacillus casei F19 (LMG P- 17806),
  • Lactobacillus acidophilus NCFB 1748, and Bifidobacterium lactis Bbl2 the bacteria are deponated at LMG culture collection in Gent, available from the NCFB culture collection and from Chr. Hansen Company DK, respectively.
  • the strains will be referred to as LMG P- 17806, NCFB 1748 and Bbl2 below.
  • Lactobacillus casei Fl 9 (LMG P- 17806), Lactobacillus acidophilus NCFB 1748, and
  • Bifidobacterium lactis Bbl2 are well characterised and the LMG P-17806 strain and its use is previously patented (WO 99/29833). The three strains survive well in food products and during the passage thrrough the gut.
  • Type II diabetes is caused by a low sensitivity to insulin or insulin resistance. This threat to human health increases continuously in all age groups all over the world. Lactobacilli as probiotics are accepted as a food product and feed product, natural product, dietary supplements, and in natural remedies, pharmaceutical active formulations and medicinal products. They are easy to use in those delivery systems and can easily be consumed on a daily basis.
  • mice After the standard breakfast above and the four hour when data on satiety and hunger were noticed the participants were offered to eat a standard lunch meal. The participants were asked to eat until they were consciously satisfied and to try to get the same level of fullness after each different breakfast. After eating the probiotic products the energy intake at lunch was 3690 KJ for the product with high level of probiotics, it was 3810 for the low level probiotic. For placebo no 1 it was 3850 and for placebo no 2 it vas 3995. This shows that the probiotic products can reduce the energy intake in a postprandial meal after eating the probiotic products as part of the breakfast. 3) Food intake of mice
  • mice of Swiss Webster strain were given acidified milk containing either LMG P-17806 or NCFB 1748 or a placebo product with the same composition but without probiotics for 10 days. The mice were between 6 and 8 weeks when the administration was started.
  • the groups given probiotics contained 7 mice in each group and the placebo group consisted of 5 animals.
  • the probiotic microrganisms were added to the products in final concentration of lxlOE8 CFU/ml and the number of bacteria was stable in the product during the feeding period.
  • the mice were given two standard daily dosages of the products, one by oral gavage feeding of 1 ml and one by sublingual injection. Both probiotic bacteria survived the passage in the gut and were present in significant numbers in the small and large intestine of the mice.
  • mice had ad libitum access to purified ingredient diet (D12450B from Research Diets Inc., New Jersey, USA).
  • the daily food intake was compared between the two groups of mice receiving Lactobacillus strains versus the placebo group of mice. The products were well tolerated by the mice.
  • mice Normal flora mice were given either an acidified milk probiotic product containing LMG P- 17806 or a placebo product with the same composition but without probiotics or kept as a control group given the same feed as the two other groups but without the acidified milk.
  • the mice strain chosen was C57B16 (Charles River) which is sensitive to diet induced obesity.
  • the number of animals included in the different groups was 15 in each of the groups given acidified milk and 3 in the control group. The mice were introduced into the study when they were 9 weeks old.
  • the number of probiotic bacteria in the product was 1x10E8 CFU/ml and the mice were allowed to eat the product ad libitum, 5 days a week, for a total number of 12 weeks.
  • mice were fed with a high fat diet (D 12309 from Research Diets Inc. New Jersey, USA containing 36% fat for the first 5 weeks and then D12492 (35% fat) from the same company for the remaining weeks of the trial). After 12 weeks the mice were sacrificed and the data on weight gain, food consumption and amount of abdominal fat was analysed. The mice given acidified milk product gained less weight than the control mice not receiving any acidified milk. The mice given acidified milk with probiotics also had a lower storage of abdominal fat compared to the group receiving acidified milk without probiotics and the control group not receiving any acidified milk at all.
  • a high fat diet D 12309 from Research Diets Inc. New Jersey, USA containing 36% fat for the first 5 weeks and then D12492 (35% fat) from the same company for the remaining weeks of the trial. After 12 weeks the mice were sacrificed and the data on weight gain, food consumption and amount of abdominal fat was analysed. The mice given acidified milk product gained less weight than the control mice not receiving any acidified milk. The mice given acidified milk
  • mice of Swiss Webster strain were given acidified milk containing either LMG P-17806 or NCFB 1748 or a placebo product with the same composition but without probiotics for 10 days.
  • the mice were between 6 and 8 weeks of age when the administration was started.
  • the groups given probiotics contained 6 mice in each group and the placebo group consisted of 4 animals.
  • the probiotic microrganisms were added to the products in final concentration of lxl0E8 CFU/ml and the number of bacteria was stable in the product during the feeding period.
  • the mice were given the product daily by oral gavage feeding. During the study the mice had ad libitum access to purified ingredient diet (D12450B from Research Diets Inc., New Jersey, USA).
  • the total dosage of the individual strains of probiotic bacteria in the different experiments described above was lxlOE8-lxlOE9 CFU (mice experiments) and 2,5xl0E8-2,5xl0E10 (human experiments).
  • This dosage needs to be administrated in a portion or as a daily dose meaning that e.g. a drink for human use that is consumed in amounts 200-500 ml need to contain 0,5xl0E6-l,25xl0E8 CFU/ml of the individual strain for efficacy and a capsule need to contain the total amount of bacteria in approximately 1 g of the content in the capsule i.e lxl0E8-2,5xl0E10. For the highest concentrations of bacteria the bacteria need to be concentrated by freeze drying or spray drying.
  • the probiotic bacteria have to be added to products based on milk, cereals or fruits.
  • the bacteria were added as a concentrate e.g. lyophilized and the survival has been analysed in all tree matrixes.
  • the survival was very good in milk based and cereal based products.
  • the survival is influenced by the fruit type.
  • the probiotic bacteria can also be added to milk based products together with other lactic acid bacteria for the production of different kinds of cultured products. In this environment the probiotic bacteria can multiply and will be well adjusted to the acid environment giving a good survival also at the low final pH in those products. The results from product production can be seen in table 1.
  • Bojrab G.. 2000 Composition and method for treatment of gastrointestinal disorders and hyperlipedemia. US patent 6 696 057

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/SE2006/001117 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity Ceased WO2007043933A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL06799717T PL1945235T3 (pl) 2005-10-07 2006-10-02 Probiotyki wpływające na metabolizm tłuszczu i otyłość
AU2006299956A AU2006299956B2 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
ES06799717T ES2396865T3 (es) 2005-10-07 2006-10-02 Probióticos para influenciar el metabolismo de las grasas y la obesidad
JP2008534487A JP2009511469A (ja) 2005-10-07 2006-10-02 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス
EP06799717A EP1945235B1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
CA002624890A CA2624890A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity
EA200800913A EA015461B1 (ru) 2005-10-07 2006-10-02 Применение пробиотических бактерий в пищевых, кормовых и лечебных продуктах
DK06799717.1T DK1945235T3 (da) 2005-10-07 2006-10-02 Probiotika til at påvirke fedtmetabolisme og fedme
SI200631495T SI1945235T1 (sl) 2005-10-07 2006-10-02 Probiotiki, ki vplivajo na presnovo maščob in debelost
BRPI0616993-7A BRPI0616993A2 (pt) 2005-10-07 2006-10-02 bactérias probióticas que influenciam o metabolismo de gordura e obesidade, bem como produtos, capsúlas e uso das mesmas
US12/089,433 US20080267933A1 (en) 2005-10-07 2006-10-02 Probiotics to Influence Fat Metabolism and Obesity
CN2006800368040A CN101287478B (zh) 2005-10-07 2006-10-02 影响脂肪代谢和肥胖的益生菌

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502214A SE529185C2 (sv) 2005-10-07 2005-10-07 Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
SE0502214-0 2005-10-07

Publications (1)

Publication Number Publication Date
WO2007043933A1 true WO2007043933A1 (en) 2007-04-19

Family

ID=37943064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2006/001117 Ceased WO2007043933A1 (en) 2005-10-07 2006-10-02 Probiotics to influence fat metabolism and obesity

Country Status (16)

Country Link
US (1) US20080267933A1 (enExample)
EP (2) EP2431044B1 (enExample)
JP (1) JP2009511469A (enExample)
CN (1) CN101287478B (enExample)
AU (1) AU2006299956B2 (enExample)
BR (1) BRPI0616993A2 (enExample)
CA (1) CA2624890A1 (enExample)
CY (1) CY1113704T1 (enExample)
DK (2) DK1945235T3 (enExample)
EA (1) EA015461B1 (enExample)
ES (2) ES2396865T3 (enExample)
PL (1) PL1945235T3 (enExample)
PT (1) PT1945235E (enExample)
SE (1) SE529185C2 (enExample)
SI (1) SI1945235T1 (enExample)
WO (1) WO2007043933A1 (enExample)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008063289A (ja) * 2006-09-08 2008-03-21 Snow Brand Milk Prod Co Ltd 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
WO2007085970A3 (en) * 2006-01-27 2008-05-08 Danisco Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
WO2009014421A1 (en) * 2007-07-25 2009-01-29 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
JP2009107956A (ja) * 2007-10-29 2009-05-21 Snow Brand Milk Prod Co Ltd アディポネクチン分泌促進及び／又は減少抑制剤
WO2009071086A3 (en) * 2007-12-06 2009-08-13 Arla Foods Amba Probiotic bacteria and regulation of fat storage
WO2010108950A1 (en) * 2009-03-25 2010-09-30 Chr. Hansen A/S Use of a probiotic to regulate body weight
WO2010108865A1 (en) 2009-03-25 2010-09-30 Chr. Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
WO2010146568A2 (en) 2009-06-19 2010-12-23 Danisco A/S Bifidobacteria for treating diabetes and related conditions
WO2010130785A3 (en) * 2009-05-12 2011-01-06 Valio Ltd Novel use of probiotics
US20110123501A1 (en) * 2007-08-17 2011-05-26 Nestec S.A. Gut flora and weight management
JP2011517570A (ja) * 2008-04-18 2011-06-16 コンパニ・ジェルベ・ダノン 抗菌特性及び免疫調節特性を有する新規なラクトバチルス・パラカゼイ亜種パラカゼイ株
WO2011096808A1 (en) 2010-02-05 2011-08-11 Friesland Brands B.V. Use of sialyl oligosaccharides in weight management
EP2359838A1 (fr) 2010-02-02 2011-08-24 Aragan Préparation destinée à traiter l`excès pondéral et les désordres associés et applications de ladite préparation
EP2276344A4 (en) * 2008-05-19 2011-09-14 Nestec Sa METHODS OF LIMITING ABSORPTION OF LIPIDS BY ANIMAL
WO2012076739A1 (es) 2010-12-07 2012-06-14 Consejo Superior De Investigaciones Científicas C.S.I.C. Bifidobacterium CECT 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas
JP2012520292A (ja) * 2009-03-10 2012-09-06 ジニス バイオファーマサティカルズ カンパニー 微生物を利用した肥満及び肥満によって引き起こされた代謝性疾患の予防と治療
WO2014072771A1 (en) 2012-11-12 2014-05-15 Compagnie Gervais Danone Lactobacillus rhamnosus strain for reducing body fat accumulation
US20140286909A1 (en) * 2011-10-18 2014-09-25 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
KR101535077B1 (ko) * 2013-09-13 2015-07-08 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
EP2320889A4 (en) * 2008-08-15 2016-09-21 Nestec Sa METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT
EP3018199A4 (en) * 2013-04-17 2016-11-30 Suntory Holdings Ltd COMPOSITION WITH A BACTERIUM OF THE GENUS LACTOBACILLUS
WO2017178316A1 (en) * 2016-04-14 2017-10-19 Dupont Nutrition Biosciences Aps Bifidobacteria for reducing food, energy and/or fat intake
WO2018145294A1 (en) 2017-02-10 2018-08-16 Perfect (China) Co., Ltd. Novel probiotics bifidobacteria strains
US20180360092A1 (en) * 2015-12-11 2018-12-20 Alimentary Health Limited Lactobacillus casei for treating obesity and associated metabolic disorders
EP3143985B1 (fr) 2009-03-04 2019-08-14 L'oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
DK2123168T3 (da) * 2008-05-16 2012-04-10 Nestec Sa Lactobacillus paracasei og vægtkontrol
RU2011135505A (ru) * 2009-03-06 2013-04-20 Федерасьон Де Продюктер Асериколь Дю Кебек Симбиотические композиции продукта из клена и способы
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
JP5436991B2 (ja) * 2009-09-10 2014-03-05 国立大学法人北海道大学 ラクトバチルス・プランタラムの菌体又は培養物を有効成分とするインスリン抵抗性改善剤
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
RU2546251C2 (ru) 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
JP5801802B2 (ja) * 2010-06-08 2015-10-28 カルピス株式会社 脂質代謝改善剤
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
ITMI20111488A1 (it) 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
KR101545551B1 (ko) 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
WO2015121458A2 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant du bifidobacterium animalis ssp. lactis
BE1000016B1 (fr) * 2014-04-25 2016-02-01 Vesale Pharma Nv Composition comprenant du bifidobacterium animalis ssp. lactis.
WO2015121455A1 (fr) * 2014-02-14 2015-08-20 Vesale Pharma Sa Composition comprenant au moins un probiotique
EP3104868A2 (fr) * 2014-02-14 2016-12-21 Vesale Pharma Sa Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
BE1000017B1 (fr) * 2014-04-25 2016-01-21 Vesale Pharma Nv Composition comprenant au moins un probiotique
WO2016020488A1 (en) * 2014-08-08 2016-02-11 Nestec S.A. Myo-inositol and probiotics and uses
CN104186655B (zh) * 2014-08-27 2016-06-29 内蒙古伊利实业集团股份有限公司 具有降血脂及抗氧化功能的低脂发酵乳及其制备方法
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
TWI640313B (zh) * 2017-08-18 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制肥胖之用途
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
FR3095761B1 (fr) 2019-05-06 2023-11-10 Lab Attitude Composition nutraceutique pour induire une perte de poids et réduire la graisse abdominale
US20230042693A1 (en) 2019-12-27 2023-02-09 Biopolis, S.L. Uses of lipoteichoic acid from bifidobacteria
CN111587952A (zh) * 2020-05-27 2020-08-28 佛山科学技术学院 一种降低家犬体脂沉积的益生菌添加剂
JP7718672B2 (ja) * 2020-12-25 2025-08-05 日清食品株式会社 腸溶コーティング錠
KR102616412B1 (ko) * 2021-07-30 2023-12-21 주식회사 메디오젠 비피도박테리움 애니말리스 락티스 mg741 균주를 포함하는 비만 또는 비알콜성 지방간 예방 또는 치료용 조성물
FR3125945B1 (fr) 2021-08-03 2024-07-12 Setalg Composition pour protéger un microorganisme dans un environnement acide.
KR102445708B1 (ko) 2021-12-02 2022-09-23 일동바이오사이언스(주) 비피도박테리움 락티스 idcc 4301을 포함하는 체지방감소용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029833A1 (en) * 1997-12-08 1999-06-17 Arlafoods Amba Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
WO2004014403A1 (en) * 2002-08-09 2004-02-19 Bioneer Corporation Microorganisms for inhibiting obesity and diabetes mellitus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61109729A (ja) * 1984-11-05 1986-05-28 Advance Res & Dev Co Ltd コレステロ−ル低下剤
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH0696537B2 (ja) * 1986-05-02 1994-11-30 雪印乳業株式会社 血清コレステロ−ル上昇抑制剤
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH107577A (ja) * 1996-06-17 1998-01-13 Yakult Honsha Co Ltd 血糖降下剤
US6641808B1 (en) * 1999-09-22 2003-11-04 Lacpro Industries, Llc Composition for treatment of obesity
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
JP2001097870A (ja) * 1999-09-30 2001-04-10 Snow Brand Milk Prod Co Ltd 乳酸菌を利用した胆汁酸の吸着方法
JP2001292728A (ja) 2000-04-13 2001-10-23 Enajikku Kk 肥満防止食品
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US6383482B1 (en) 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6963306B2 (en) * 2001-02-02 2005-11-08 Rosum Corp. Position location and data transmission using pseudo digital television transmitters
EP1344458A1 (en) * 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US6565847B1 (en) 2002-07-03 2003-05-20 Vitacost.Com, Inc. Thermogenic weight management composition
US20040014403A1 (en) * 2002-07-16 2004-01-22 Oberkampf Brandon L. CMP point of use filtration
ATE354964T1 (de) * 2003-05-22 2006-03-15 Synbiotics Ab Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
US20060093592A1 (en) 2004-10-04 2006-05-04 Nutracea Synbiotics
EP2227239A2 (en) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotic bacteria and regulation of fat storage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029833A1 (en) * 1997-12-08 1999-06-17 Arlafoods Amba Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
WO2004014403A1 (en) * 2002-08-09 2004-02-19 Bioneer Corporation Microorganisms for inhibiting obesity and diabetes mellitus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KALAVATHY R. ET AL.: "Effects of Lactobacillus cultures on growth performance, abdominal fat deposition, serum lipids and weight of organs of broiler chickens", BRITISH POULTRY SCIENCE, vol. 44, 2003, pages 139 - 144, XP003009318 *
MATSUZAKI T. ET AL.: "Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, buy oral feeding of Lactobacillus casei", APMIS, vol. 105, no. 8, 1997, pages 643 - 649, XP003009319 *
TABUCHI M. ET AL.: "Antidiabetic Effect of Lactobacillus GG in Streptozotocin-induced Diabetic Rats", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 67, no. 6, 2003, pages 1421 - 1424, XP003009317 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524640A (ja) * 2006-01-27 2009-07-02 ダニスコ エー／エス 肥満及びそれに関連する疾患の治療及び予防のためのプロバイオティック微生物の使用
WO2007085970A3 (en) * 2006-01-27 2008-05-08 Danisco Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
US8257695B2 (en) 2006-01-27 2012-09-04 Dupont Nutrition Biosciences Aps Method for modulating satiety signaling with specific strains of Lactobacillus acidophilus and Bacillus
JP2008063289A (ja) * 2006-09-08 2008-03-21 Snow Brand Milk Prod Co Ltd 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
AU2008270285B2 (en) * 2007-07-05 2014-09-11 Nestec S.A. Supplemention of maternal diet
US9636369B2 (en) 2007-07-05 2017-05-02 Nestec S.A. Supplemention of maternal diet
EP3120858A1 (en) * 2007-07-05 2017-01-25 Nestec S.A. Supplementation of maternal diet
WO2009004076A3 (en) * 2007-07-05 2009-09-24 Nestec S.A. Supplemention of maternal diet
US9308228B2 (en) 2007-07-05 2016-04-12 Nestec S.A. Supplemention of maternal diet
US8658156B2 (en) 2007-07-05 2014-02-25 Nestec S.A. Supplemention of maternal diet
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
RU2464995C2 (ru) * 2007-07-05 2012-10-27 Нестек С.А. Добавка к материнской диете
WO2009014421A1 (en) * 2007-07-25 2009-01-29 Campina Nederland Holding B.V. Probiotics for inducing satiety and/or satiation
US8591880B2 (en) 2007-08-17 2013-11-26 Nestec S.A. Gut flora and weight management
US20110123501A1 (en) * 2007-08-17 2011-05-26 Nestec S.A. Gut flora and weight management
JP2009107956A (ja) * 2007-10-29 2009-05-21 Snow Brand Milk Prod Co Ltd アディポネクチン分泌促進及び／又は減少抑制剤
EP2210609A4 (en) * 2007-10-29 2011-04-13 Snow Brand Milk Products Co Ltd MEDIUM TO PROMOTE THE SECRETION OF ADIPONECTIN AND / OR TO PREVENT THE ACCEPTANCE OF ADIPONECTIN SECRETION
WO2009071086A3 (en) * 2007-12-06 2009-08-13 Arla Foods Amba Probiotic bacteria and regulation of fat storage
US9113641B2 (en) 2007-12-06 2015-08-25 Arla Foods Amba Probiotic bacteria and regulation of fat storage
US20110150852A1 (en) * 2008-04-18 2011-06-23 Isabelle Chambaud Novel Strain of Lactobacillus Paracasei Subspecies Paracasei Having Antimicrobial and Immunomodulatory Properties
JP2011517570A (ja) * 2008-04-18 2011-06-16 コンパニ・ジェルベ・ダノン 抗菌特性及び免疫調節特性を有する新規なラクトバチルス・パラカゼイ亜種パラカゼイ株
US8557561B2 (en) * 2008-04-18 2013-10-15 Compagnie Gervais Danone Strain of Lactobacillus paracasei having antimicrobial and immunomodulatory properties
EP2276344A4 (en) * 2008-05-19 2011-09-14 Nestec Sa METHODS OF LIMITING ABSORPTION OF LIPIDS BY ANIMAL
AU2009249582B2 (en) * 2008-05-19 2014-07-31 Nestec S.A. Methods for reducing lipid absorption by an animal
EP2320889A4 (en) * 2008-08-15 2016-09-21 Nestec Sa METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT
EP3143985B1 (fr) 2009-03-04 2019-08-14 L'oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
JP2012520292A (ja) * 2009-03-10 2012-09-06 ジニス バイオファーマサティカルズ カンパニー 微生物を利用した肥満及び肥満によって引き起こされた代謝性疾患の予防と治療
EP2407170A4 (en) * 2009-03-10 2012-11-21 Jinis Biopharmaceuticals Co PREVENTION AND TREATMENT OF FAT SUPPORT AND METABOLISM-RELATED METABOLISM DISEASES WITH MICRO-ORGANISMS
CN102448477A (zh) * 2009-03-25 2012-05-09 科·汉森有限公司 益生菌在调节体重中的用途
WO2010108865A1 (en) 2009-03-25 2010-09-30 Chr. Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
WO2010108950A1 (en) * 2009-03-25 2010-09-30 Chr. Hansen A/S Use of a probiotic to regulate body weight
WO2010130785A3 (en) * 2009-05-12 2011-01-06 Valio Ltd Novel use of probiotics
WO2010146568A2 (en) 2009-06-19 2010-12-23 Danisco A/S Bifidobacteria for treating diabetes and related conditions
WO2010146568A3 (en) * 2009-06-19 2011-05-05 Danisco A/S Bifidobacteria for treating diabetes and related conditions
EP2808024A1 (en) 2009-06-19 2014-12-03 Dupont Nutrition Biosciences ApS Bifidobacteria for Treating myocardial infarction
EP3181134A1 (en) 2009-06-19 2017-06-21 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
EP2359838A1 (fr) 2010-02-02 2011-08-24 Aragan Préparation destinée à traiter l`excès pondéral et les désordres associés et applications de ladite préparation
WO2011096808A1 (en) 2010-02-05 2011-08-11 Friesland Brands B.V. Use of sialyl oligosaccharides in weight management
ES2389547A1 (es) * 2010-12-07 2012-10-29 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
EP2650002A4 (en) * 2010-12-07 2014-08-13 Consejo Superior Investigacion BIFIDOBACTERIUM CECT 7765 AND ITS USE IN THE PREVENTION AND / OR TREATMENT OF OVERWEIGHT, ADIPOSITAS AND SIMILAR ILLNESS
WO2012076739A1 (es) 2010-12-07 2012-06-14 Consejo Superior De Investigaciones Científicas C.S.I.C. Bifidobacterium CECT 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas
US20140286909A1 (en) * 2011-10-18 2014-09-25 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
US9636367B2 (en) * 2011-10-18 2017-05-02 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
WO2014072771A1 (en) 2012-11-12 2014-05-15 Compagnie Gervais Danone Lactobacillus rhamnosus strain for reducing body fat accumulation
US10159269B2 (en) 2013-04-17 2018-12-25 Suntory Holdings Limited Composition containing bacterium belonging to genus Lactobacillus
EP3018199A4 (en) * 2013-04-17 2016-11-30 Suntory Holdings Ltd COMPOSITION WITH A BACTERIUM OF THE GENUS LACTOBACILLUS
US9603880B2 (en) 2013-04-17 2017-03-28 Suntory Holdings Limited Composition containing bacterium belonging to genus lactobacillus
KR101535077B1 (ko) * 2013-09-13 2015-07-08 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 가지는 비피도박테리움 락티스 hy8101 및 이를 유효성분으로 함유하는 제품
US20180360092A1 (en) * 2015-12-11 2018-12-20 Alimentary Health Limited Lactobacillus casei for treating obesity and associated metabolic disorders
US11490643B2 (en) * 2015-12-11 2022-11-08 Precisionbiotics Group Limited Lactobacillus casei for treating obesity and associated metabolic disorders
CN109069554A (zh) * 2016-04-14 2018-12-21 杜邦营养生物科学有限公司 用于降低食物、能量和/或脂肪摄入的双歧杆菌
WO2017178316A1 (en) * 2016-04-14 2017-10-19 Dupont Nutrition Biosciences Aps Bifidobacteria for reducing food, energy and/or fat intake
AU2017249661B2 (en) * 2016-04-14 2020-03-19 International N&H Denmark Aps Bifidobacteria for reducing food, energy and/or fat intake
RU2762096C2 (ru) * 2016-04-14 2021-12-15 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Бифидобактерии для снижения потребления пищи, энергии и/или жиров
WO2018145294A1 (en) 2017-02-10 2018-08-16 Perfect (China) Co., Ltd. Novel probiotics bifidobacteria strains
US11607435B2 (en) 2017-02-10 2023-03-21 Perfect (China) Co., Ltd. Probiotics Bifidobacteria strains

Also Published As

Publication number Publication date
SI1945235T1 (sl) 2013-02-28
BRPI0616993A2 (pt) 2011-07-05
EP1945235A4 (en) 2009-11-11
ES2396865T3 (es) 2013-02-28
EA200800913A1 (ru) 2008-10-30
DK1945235T3 (da) 2013-01-14
SE529185C2 (sv) 2007-05-22
CN101287478A (zh) 2008-10-15
AU2006299956A1 (en) 2007-04-19
PL1945235T3 (pl) 2013-03-29
SE0502214L (sv) 2007-04-08
EP1945235A1 (en) 2008-07-23
CY1113704T1 (el) 2016-06-22
EA015461B1 (ru) 2011-08-30
EP2431044A1 (en) 2012-03-21
DK2431044T3 (en) 2016-04-11
PT1945235E (pt) 2013-01-14
EP1945235B1 (en) 2012-09-26
ES2567404T3 (es) 2016-04-22
AU2006299956B2 (en) 2012-03-15
JP2009511469A (ja) 2009-03-19
CN101287478B (zh) 2012-10-03
EP2431044B1 (en) 2016-01-13
CA2624890A1 (en) 2007-04-19
US20080267933A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
AU2006299956B2 (en) Probiotics to influence fat metabolism and obesity
CN100502888C (zh) 来自乳酸菌的脂磷壁酸及其调节革兰氏阴性菌、可能致病的革兰氏阳性菌介导的免疫应答的用途
EP2442814B1 (en) Bifidobacteria for treating diabetes and related conditions
Kalantzopoulos Fermented products with probiotic qualities
US10543239B2 (en) Lactic acid bacteria and bifidobacteria for treating endotoxemia
US20190083551A1 (en) Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
US20120027737A1 (en) Use of probiotics to ameliorate diet-induced insulin resistance
KR20190116248A (ko) 신규한 프로바이오틱스 비피도박테리움 균주
EP3909589B1 (en) Liquid probiotic-herbal preparation
AU2022302837B2 (en) Composition comprising three lactobacillus sp. strains, and use thereof
JP2025537795A (ja) リモシラクトバチルス・ムコサエ（Ｌｉｍｏｓｉｌａｃｔｏｂａｃｉｌｌｕｓ ｍｕｃｏｓａｅ）及びＧＬＰ－１増加を必要とする障害
MX2008004578A (en) Probiotics to influence fat metabolism and obesity
Singhal et al. Therapeutic Effects of Gut Microbiota on Metabolic Syndrome: A Patent Review
Prapaipat et al. World Journal of Advanced Research and Reviews
Varzakas et al. 12 Functional Dairy Foods and Flora Modulation
Sharma et al. 13 Probiotics and Its Efficacy Assessment in Diabetic Intervention
Workouts et al. Probiotic Roundup

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680036804.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006299956

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008534487

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2624890

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004578

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 567274

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2006299956

Country of ref document: AU

Date of ref document: 20061002

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200800913

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: DZP2008000288

Country of ref document: DZ

Ref document number: 2006799717

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12089433

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0616993

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080407